my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
07-03-2012: Medicyte and PRIMACYT have received a 300k Euro grant from the BMBF to develop culturing methods of human hepatocytes for use in cell-based therapies.
Cell-based therapies and the development of transplantable bioartificial livers to treat severe liver diseases still fail due to the limited availability of appropriate cells in large numbers and clinical quality. These failures are often related to the complex and difficult culturing of liver cells.
Medicyte’s upcyte® technology enables the expansion of human primary liver cells to large amounts and with consistent quality. Upcyte® hepatocytes are functionally equivalent to human primary liver cells and therefore suitable for use in cell-based bioartificial liver systems. PRIMACYT’s main expertise lies in the serum-free, long-term culturing of primary human hepatocytes and the development of cell culture media. Both companies now combine their knowledge to develop modified liver cells in large amounts for use in cell-based therapies.
The three-year project is supported by a team from the University of Tübingen lead by Prof. Andreas Nüssler, a well-known liver cell expert. The Federal Ministry of Education and Research (BMBF) is supporting the joint effort out of the grant program “KMU-innovativ”.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Medicyte Coordinates EU-funded Collaboration on Biomimetic Bioartificial Liver
Medicyte and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.The aim of Re-Liver is to reconstitute a standardized and reproducible b ... more
Medicyte Awarded ISO 9001 Certification
Offering a new and unique technology to propagate primary human cells to virtually unlimited numbers, Medicyte has now gone a step further in its high quality policy. As announced, its quality management system was certified in December 2011 to meet the criteria of the globally recognized s ... more
Medicyte and PRIMACYT Receive Grant to Develop Human Liver Cells for Cell-based Therapies
Medicyte and PRIMACYT have received a 300k Euro grant from the BMBF to develop culturing methods of human hepatocytes for use in cell-based therapies.Cell-based therapies and the development of transplantable bioartificial livers to treat severe liver diseases still fail due to the limited ... more
Medicyte and PRIMACYT Receive Grant to Develop Human Liver Cells for Cell-based Therapies
Medicyte and PRIMACYT have received a 300k Euro grant from the BMBF to develop culturing methods of human hepatocytes for use in cell-based therapies.Cell-based therapies and the development of transplantable bioartificial livers to treat severe liver diseases still fail due to the limited ... more
Bionas and PRIMACYT have entered into a cooperation aimed at the development of a cell-based assay using primary human hepatocytes for prediction of hepatotoxic effects in response to test compounds. Primary human hepatocytes, provided by PRIMACYT, are cultivated directly on collagen-coate ... more
German Biotech Companies Report New Results on Cultivated Liver Cells
Prediction of toxicity and compound responses in hepatocytes continues to be a major concern for the pharmaceutical industry. Non-immortalised primary cells may best represent normal physiology. The German biotech company Bionas GmbH has made a first study investigating primary human hepato ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
